Altamira Therapeutics Ltd. Research And Development Expense
Altamira Therapeutics Ltd. (CYTOF) reported Research And Development Expense of $1.47 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-08-29.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2025-08-29
CHF
| Period end | Research And Development Expense 6 month | Research And Development Expense 12 month | Research And Development Expense 12 month as first filed |
|---|---|---|---|
| 2023-12-31 | 3.04M CHF 20-F/A · filed 2024-04-22 | ||
| 2023-06-30 | 2.26M CHF 6-K · filed 2023-09-12 | ||
| 2022-12-31 | 14.62M CHF 20-F/A · filed 2024-04-22 | 19.68M CHF 20-F · filed 2023-05-16 | |
| 2022-06-30 | 3.56M CHF 6-K · filed 2023-09-12 | ||
| 2021-12-31 | 3.20M CHF 20-F/A · filed 2024-04-22 | 8.94M CHF 20-F · filed 2022-04-12 | |
| 2021-06-30 | 3.39M CHF 6-K/A · filed 2023-08-21 | ||
| 2020-12-31 | 2.86M CHF 20-F · filed 2023-05-16 | ||
| 2020-06-30 | 884.75K CHF 6-K · filed 2021-09-08 | ||
| 2019-12-31 | 3.33M CHF 20-F · filed 2022-04-12 | ||
| 2019-06-30 | 1.30M CHF 6-K/A · filed 2020-09-17 | ||
| 2018-12-31 | 6.69M CHF 20-F · filed 2021-03-31 | ||
| 2018-06-30 | 4.96M CHF 6-K · filed 2019-08-15 | ||
| 2017-12-31 | 19.21M CHF 20-F · filed 2020-04-16 | ||
| 2016-12-31 | 24.78M CHF 20-F · filed 2019-03-14 | ||
| 2015-12-31 | 26.54M CHF 20-F · filed 2018-03-22 |
USD
| Period end | Research And Development Expense 6 month | Research And Development Expense 12 month |
|---|---|---|
| 2025-06-30 | $1.47M 6-K · filed 2025-08-29 | |
| 2024-12-31 | $3.73M 20-F · filed 2025-04-30 | |
| 2024-06-30 | $1.96M 6-K · filed 2025-08-29 | |
| 2023-12-31 | $3.38M 20-F · filed 2025-04-30 | |
| 2023-06-30 | $1.48M 6-K · filed 2024-09-24 | |
| 2022-12-31 | $15.31M 20-F · filed 2025-04-30 |